Safety of a remote disease management program to improve sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists prescribing in type 2 diabetes with elevated cardiovascular or kidney risk.

What Was Tested

This randomized controlled trial looks at Glucagon.

Registry: ClinicalTrials.gov; URL: https://clinicaltrials.gov/study/NCT06046560; unique identifier: NCT06046560.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

The DRIVE trial was a pragmatic, randomized clinical trial evaluating the safety of a remote disease management program that initiated SGLT2i and/or GLP1 RA in patients with T2D and elevated cardiovascular or kidney risk.

Participants were enrolled at a large integrated health care system in Massachusetts between March 2021 and December 2022.

How the Study Was Run

The researchers set it up as a randomized study.

Because people in this Glucagon study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Participants were randomized to 1 of 2 implementation strategies: a sequential approach (two months of education first followed by medication initiation) or a bundled approach (simultaneous education and medication initiation).

Targeted AEs were prospectively collected over the first 6 months after enrollment: for SGLT2i initiators, symptoms of genital mycotic infection, urinary tract infection, or volume depletion; for GLP 1 RA initiators, nausea, vomiting, diarrhea, and abdominal pain.

Hospitalizations, emergency department visits, and urgent care visits over the first 6 months after enrollment were retrospectively collected through electronic health record review.

What Was Measured

The subject headings attached to it are Cardiovascular Diseases, Diabetes Mellitus, Type 2, Disease Management, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents and Sodium-Glucose Transporter 2 Inhibitors.

What This Means in Plain Language

The paper is a randomized study of Glucagon.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2026 (American heart journal), a journal based in United States.

More context: the Glucagon compound page, all human trials.